Purdue Pharma: Innovative Healthcare Solutions

Purdue Pharma Announces Landmark Agreement with Oklahoma
to Advance the Treatment of Addiction

Mar 26, 2019

Settlement will establish national center for addiction studies and treatment in Tulsa; Sackler family announces voluntary contribution to ... Read more

FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the
Emergency Treatment of Known or Suspected Opioid Overdose

Mar 13, 2019

Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene HCl STAMFORD, ... Read more

Purdue Pharma Statement to 60 Minutes Regarding the Segment on Opioid Medicines
Expected to Air Sunday, February 24, 2019

Feb 22, 2019

In 1995, the U.S. Food and Drug Administration (FDA) approved OxyContin® (oxycodone HCI) extended-release tablets CII (current Full ... Read more

Patients Who Receive Information About the Importance of Safe Disposal are Three Times More Likely to Dispose of Unused Prescription Opioid Medications

Feb 20, 2019

Survey study sponsored by Purdue Pharma and published in the Journal of Pain Research examines factors that contribute ... Read more

Eisai and Purdue Pharma Present Efficacy and Safety Data from
Second Pivotal Phase 3 Study at the Sleep Research Society’s Conference:
Advances in Sleep and Circadian Science

Feb 4, 2019

Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant ... Read more

Purdue Pharma L.P. and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment

Jan 28, 2019

Alivio to receive up to $14.75 million in upfront and near-term license exercise payments and is eligible to ... Read more

On-Road Driving Safety Study of
Investigational Lemborexant Published in SLEEP^®

Jan 22, 2019

Lemborexant taken at bedtime had no significant effect on automobile driving performance the next morning in healthy adult ... Read more

New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States

Jan 15, 2019

TOKYO and STAMFORD, Conn. – January 15, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue ... Read more

Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain

Jan 7, 2019

Partners to research novel targets for reductions in pain STAMFORD, Conn., and BEDFORD, Mass., January 7, 2019 – ... Read more

First Patient Enrolled in Investigator-Initiated Study of Tinostamustine in Glioblastoma

Nov 6, 2018

STAMFORD, Conn., November 6, 2018 – Purdue Pharma L.P. today announced that the first patient has been enrolled in a ... Read more

More news

Recent News